Status:
UNKNOWN
Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Dyspnea is a major symptom in pulmonary arterial hypertension and people with the same haemodynamic have generally different degree of dyspnea in pulmonary arterial hypertension. The hyperventilation ...
Detailed Description
Hyperventilation syndrome has been described as a cause of dyspnea in the general population and in several chronic respiratory diseases such as asthma with 20 to 40% of asthmatics affected. However, ...
Eligibility Criteria
Inclusion
- Non smoker or tobacco stopped for minimum 2 years ans maximum 10 year-pack. - Idiopathic, heritable, related to drug or toxics, associated with controlled pulmonary hypertension. Diagnosis and treatment of pulmonary hypertension for more than 4 months.
- Optimal control of pulmonary hypertension (no right heart failure symptom and NTproBNP \< 300ng/L or Brain Natriuretic Peptide(BNP) \< 50 ng/L and optimal hemodynamic results measured by a right heart catheterization in the last year: right atrial pressure \< 8 mmHg, cardiac index \> 2,5 L/min/m2, veinous saturation in oxygen \> 65%)
- Informed and written consent
- Non-affiliation to a social security
Exclusion
- Existence of another form of pulmonary hypertension
- Existence of vocal cord dysfunction
- Pregnancy
- Obesity\> stage 2 (BMI 35 kg / m2)
- Age ≥ 75 years
Key Trial Info
Start Date :
January 14 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 14 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03810443
Start Date
January 14 2019
End Date
July 14 2021
Last Update
January 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Bicêtre - Pneumology department
Le Kremlin-Bicêtre, France, 94270